CN111819172B - 用于治疗与神经营养蛋白有关的疾病的三嗪衍生物 - Google Patents

用于治疗与神经营养蛋白有关的疾病的三嗪衍生物 Download PDF

Info

Publication number
CN111819172B
CN111819172B CN201980014798.6A CN201980014798A CN111819172B CN 111819172 B CN111819172 B CN 111819172B CN 201980014798 A CN201980014798 A CN 201980014798A CN 111819172 B CN111819172 B CN 111819172B
Authority
CN
China
Prior art keywords
methyl
phenoxyphenyl
phenyl
trione
triazinane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980014798.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111819172A (zh
Inventor
G·诺得瓦尔
P·福塞尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aztec Pharmaceuticals
Original Assignee
Aztec Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1810667.4A external-priority patent/GB201810667D0/en
Application filed by Aztec Pharmaceuticals filed Critical Aztec Pharmaceuticals
Publication of CN111819172A publication Critical patent/CN111819172A/zh
Application granted granted Critical
Publication of CN111819172B publication Critical patent/CN111819172B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • C07D251/34—Cyanuric or isocyanuric esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980014798.6A 2018-02-26 2019-02-26 用于治疗与神经营养蛋白有关的疾病的三嗪衍生物 Active CN111819172B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1850217 2018-02-26
SE1850217-9 2018-02-26
GBGB1810667.4A GB201810667D0 (en) 2018-06-28 2018-06-28 New compounds and uses
GB1810667.4 2018-06-28
PCT/GB2019/050523 WO2019162702A1 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins

Publications (2)

Publication Number Publication Date
CN111819172A CN111819172A (zh) 2020-10-23
CN111819172B true CN111819172B (zh) 2024-02-06

Family

ID=65729389

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980014798.6A Active CN111819172B (zh) 2018-02-26 2019-02-26 用于治疗与神经营养蛋白有关的疾病的三嗪衍生物

Country Status (24)

Country Link
US (3) US11352332B2 (https=)
EP (1) EP3759088B8 (https=)
JP (1) JP7350759B2 (https=)
KR (1) KR102782749B1 (https=)
CN (1) CN111819172B (https=)
AU (1) AU2019223333B2 (https=)
BR (1) BR112020017341A2 (https=)
CA (1) CA3090864A1 (https=)
CL (1) CL2020002157A1 (https=)
DK (1) DK3759088T3 (https=)
ES (1) ES2941529T3 (https=)
FI (1) FI3759088T3 (https=)
HR (1) HRP20230290T1 (https=)
HU (1) HUE061751T2 (https=)
IL (1) IL276624B2 (https=)
LT (1) LT3759088T (https=)
MA (1) MA52415A (https=)
MX (1) MX2020008816A (https=)
PL (1) PL3759088T3 (https=)
PT (1) PT3759088T (https=)
SG (1) SG11202007136VA (https=)
SI (1) SI3759088T1 (https=)
WO (1) WO2019162702A1 (https=)
ZA (1) ZA202004220B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110709255B (zh) * 2017-06-08 2021-08-06 日本曹达株式会社 记录材料及化合物
MX2020008816A (es) 2018-02-26 2020-09-28 AlzeCure Pharma AB Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) * 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds
CN113831298B (zh) * 2020-06-23 2023-12-01 沈阳中化农药化工研发有限公司 光活性羧酸酯类化合物及其应用
AU2021297861B2 (en) * 2020-06-23 2024-03-07 Jiangsu Yangnong Chemical Co., Ltd. Triazine benzoate compound and application thereof
CN113831299B (zh) * 2020-06-23 2023-12-01 沈阳中化农药化工研发有限公司 苯甲酸酯类化合物及其应用
KR102770474B1 (ko) * 2021-03-23 2025-02-21 한국과학기술연구원 신규한 화합물 및 이를 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
WO2024131834A1 (zh) * 2022-12-21 2024-06-27 沈阳中化农药化工研发有限公司 一种除草组合物及其应用
WO2025232990A1 (en) 2024-05-09 2025-11-13 AlzeCure Pharma AB Triazinone derivatives for use in the treatment of inflammation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933814A (en) * 1972-09-20 1976-01-20 Bayer Aktiengesellschaft 1-(4-Phenoxyphenyl)-1,3,5-triazines
US3948893A (en) * 1973-03-20 1976-04-06 Bayer Aktiengesellschaft 1-Phenyl-substituted 1,3,5-triazines
US3966725A (en) * 1974-03-21 1976-06-29 Bayer Aktiengesellschaft 1-(4-Phenoxy-phenyl)-1,3,5-triazines
EP0081142A2 (de) * 1981-12-03 1983-06-15 BASF Aktiengesellschaft 1,3,5-Triazinone, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
EP0279219A1 (de) * 1987-02-03 1988-08-24 Bayer Ag Mittel gegen Protozoen bei Insekten
WO2018115891A1 (en) * 2016-12-21 2018-06-28 Stiftelsen Alzecure Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718799A1 (de) 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
DE3314739A1 (de) 1983-04-23 1984-10-25 Bayer Ag, 5090 Leverkusen 1-(4-(4-(fluoralkylmethylthio- oder -sulfinyl- oder -sulfonyl-)phenoxy) phenyl)-1,3,5-triazin-2,4,6(1h,3h,5h)-trione, verfahren zu ihrer herstellung und ihre verwendung als coccidiosemittel
DE3408768A1 (de) * 1984-03-09 1985-09-12 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
DE3516632A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1,3,5-triazintrionen
DE3516631A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 3-methyl-1,3,5-triazintrionen
DE3810080A1 (de) 1988-03-25 1989-10-05 Bayer Ag Trisubstituierte 1,3,5-triazin-2,4,6-trione
DE3814323A1 (de) 1988-04-28 1989-11-09 Hoechst Ag Wasserloesliche zubereitungen von coccidiostatica
US4933341A (en) 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
DE4000624A1 (de) 1990-01-11 1991-07-18 Bayer Ag Fungizide verwendung von trisubstituierten 1,3,5-triazin-2,4,6-trionen, neue trisubstituierte 1,3,5-triazin-2,4,6-trione und verfahren zu ihrer herstellung
DE4329096A1 (de) 1993-08-30 1995-03-02 Bayer Ag Heterocyclylbenzoheterocyclen
US5726126A (en) 1995-06-02 1998-03-10 American Cyanamid Company 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents
US5604180A (en) 1995-06-02 1997-02-18 Crews, Jr.; Alvin D. 3-(3-aryloxyphenyl)-1 (substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
CZ146296A3 (en) 1995-06-02 1997-04-16 American Cyanamid Co 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotriones, process of their preparation and herbicidal agents
US5519133A (en) 1995-06-02 1996-05-21 American Cyanamid Co. 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
US5679791A (en) 1996-07-25 1997-10-21 American Cyanamid Company 1-(3-heterocyclylphenyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
AU766542B2 (en) 1998-10-08 2003-10-16 New Ace Research Company Novel compositions and methods for prevention and treatment of protozoal disease
CN1331595A (zh) 1998-12-22 2002-01-16 美国拜尔公司 肉孢子虫属、新孢子虫属(Neospora)和弓形虫属引起的疾病治疗用三嗪酮化合物
DE19937500A1 (de) 1999-08-09 2001-02-15 Bayer Ag Substituierte Heterocyclylbenzofurane
DE19958388A1 (de) 1999-12-03 2001-06-07 Bayer Ag Triazinonverbindungen zur Behandlung von durch den Befall mit parasitischen Protozoen bedingten Krankheiten
US6444615B1 (en) 2000-04-18 2002-09-03 Dow Agrosciences Llc Herbicidal imidazolidinetrione and thioxo-imidazolidinediones
DE10034800A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Benzostickstoffheterocyclen
DE10040174A1 (de) 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen
DE10040110A1 (de) 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfoxiden zur Bekämpfung von Coccidiosen
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
US20040259912A1 (en) 2001-09-28 2004-12-23 Takahiro Matsumoto Benzine derivatives, process for preparing the same and use thereof
US6861523B2 (en) 2002-02-08 2005-03-01 Torrey Pines Institute For Molecular Studies 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries
WO2003101980A1 (en) 2002-05-30 2003-12-11 Solvay Pharmaceuticals B.V. 1,3,5-triazine derivatives as ligands for human adenosine-a3 receptors
WO2004007499A1 (en) 2002-07-15 2004-01-22 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
DE102006038292A1 (de) 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen
WO2008148008A1 (en) 2007-05-23 2008-12-04 Emory University High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity
US20120004310A1 (en) 2010-05-28 2012-01-05 Longo Frank M Non-peptide bdnf neurotrophin mimetics
CN105209427B (zh) 2013-03-15 2018-05-25 特罗菲克斯制药股份有限公司 非肽bdnf神经营养蛋白模拟物
KR101861942B1 (ko) 2014-01-20 2018-06-29 에프. 호프만-라 로슈 아게 신경 발생을 자극할 수 있는 n-페닐-락탐 유도체 및 이의 신경 장애 치료에서의 용도
EP3229611B1 (en) 2014-12-10 2025-03-26 Mars, Incorporated Compounds that modulate fatty acid receptor activity and pet food products containing the same
MX2020008816A (es) 2018-02-26 2020-09-28 AlzeCure Pharma AB Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
GB201810669D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933814A (en) * 1972-09-20 1976-01-20 Bayer Aktiengesellschaft 1-(4-Phenoxyphenyl)-1,3,5-triazines
US3948893A (en) * 1973-03-20 1976-04-06 Bayer Aktiengesellschaft 1-Phenyl-substituted 1,3,5-triazines
US3966725A (en) * 1974-03-21 1976-06-29 Bayer Aktiengesellschaft 1-(4-Phenoxy-phenyl)-1,3,5-triazines
EP0081142A2 (de) * 1981-12-03 1983-06-15 BASF Aktiengesellschaft 1,3,5-Triazinone, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
EP0279219A1 (de) * 1987-02-03 1988-08-24 Bayer Ag Mittel gegen Protozoen bei Insekten
WO2018115891A1 (en) * 2016-12-21 2018-06-28 Stiftelsen Alzecure Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R.B.西尔弗曼.生物电子等排.《有机药物化学》.2008, *

Also Published As

Publication number Publication date
EP3759088B8 (en) 2023-03-08
US20200399230A1 (en) 2020-12-24
US20220306589A1 (en) 2022-09-29
SG11202007136VA (en) 2020-08-28
EP3759088B1 (en) 2023-01-25
LT3759088T (lt) 2023-05-10
SI3759088T1 (sl) 2023-07-31
RU2020126542A (ru) 2022-03-29
IL276624A (en) 2020-09-30
ES2941529T3 (es) 2023-05-23
US20250214948A1 (en) 2025-07-03
KR102782749B1 (ko) 2025-03-18
CA3090864A1 (en) 2019-08-29
JP7350759B2 (ja) 2023-09-26
CL2020002157A1 (es) 2020-12-18
IL276624B1 (en) 2023-06-01
HUE061751T2 (hu) 2023-08-28
AU2019223333B2 (en) 2024-06-20
US11352332B2 (en) 2022-06-07
US12209071B2 (en) 2025-01-28
KR20200126988A (ko) 2020-11-09
DK3759088T3 (en) 2023-03-27
AU2019223333A1 (en) 2020-08-27
MX2020008816A (es) 2020-09-28
WO2019162702A1 (en) 2019-08-29
IL276624B2 (en) 2023-10-01
PT3759088T (pt) 2023-04-10
CN111819172A (zh) 2020-10-23
HRP20230290T1 (hr) 2023-05-26
JP2021514963A (ja) 2021-06-17
FI3759088T3 (fi) 2023-04-05
PL3759088T3 (pl) 2023-07-03
BR112020017341A2 (pt) 2020-12-15
EP3759088A1 (en) 2021-01-06
ZA202004220B (en) 2023-12-20
MA52415A (fr) 2021-01-06

Similar Documents

Publication Publication Date Title
CN111819172B (zh) 用于治疗与神经营养蛋白有关的疾病的三嗪衍生物
ES2793723T3 (es) Compuesto heterocíclico y uso del mismo como modulador alostérico positivo del receptor ampa
WO2017170830A1 (ja) 複素環化合物
WO2011016559A1 (ja) 複素環化合物およびその用途
CN106536508A (zh) 用于治疗阿尔茨海默病的具有胆碱能毒蕈碱m1受体正变构调节剂活性的异吲哚啉‑1‑酮衍生物
CN112513032B (zh) 作为trk受体的调节剂的4-取代的苯基-1,3,5-三嗪衍生物
KR20190098982A (ko) 트리아진트리온 유도체 및 뉴로트로핀 수용체 및 수용체 티로신 키나제의 조절제로서의 이의 용도
CN114423743A (zh) 用于治疗与神经营养因子相关的疾病的三嗪衍生物
CN112703187A (zh) 作为trk受体的调节剂的4-取代的苯基-1,3,5-三嗪衍生物
WO2021020362A1 (ja) 複素環化合物
RU2816837C2 (ru) Производные триазина для лечения заболеваний, связанных с нейротрофинами
HK40033844A (en) Triazine derivatives for treating diseases relating to neurotrophins
HK40033844B (en) Triazine derivatives for treating diseases relating to neurotrophins
JP7628955B2 (ja) 複素環化合物
HK1182701B (en) Heterocyclic compound and use thereof as ampa receptor positive allosteric modulator
HK1182701A (en) Heterocyclic compound and use thereof as ampa receptor positive allosteric modulator

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant